Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure

Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN;
TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading
European pharmaceutical and medical devices company, today
announced the receipt of initial orders for Vasogen's Celacade(TM)
System in Germany. Celacade, a first-in-class therapy, is the only CE
Mark approved product that specifically targets the destructive
chronic inflammation underlying the development and progression of
chronic heart failure. Under the CE Mark, Celacade can be marketed
in the 27 countries that comprise the European Union and is
indicated in the EU for the treatment of New York Heart Association
(NYHA) Class II patients and NYHA Class II, III, & IV heart failure
patients who do not have a prior history of heart attack.

In the international ACCLAIM trial, Celacade was shown to
significantly reduce the risk of death or cardiovascular
hospitalizations in large pre-specified subgroups of patients with
chronic heart failure, including NYHA Class II patients, where risk
was reduced by 39%, and NYHA Class II to IV patients with no prior
heart attack, where risk was reduced by 26%. The commercial
introduction of Celacade in the European Union provides physicians
and patients with a novel approach for the treatment of heart failure
that is safe and well tolerated and can be used in combination with
currently approved therapies for this condition.

"The initial orders for the Celacade System are a major milestone
for Vasogen," commented Chris Waddick, President and CEO of Vasogen.
"We are extremely pleased that Ferrer has secured these orders so
quickly after completing key pre-marketing activities. We look
forward to continuing our close collaboration with Ferrer as we work
to rapidly expand the use of Celacade within the European Union."

"We are firmly committed to the success of Celacade in Europe,"
commented Dr. Carlos de Lecea, Vice President International and
Business Development at Ferrer. "We are very pleased that the
initial orders are from sites who participated in the ACCLAIM study,
which we believe reflects the clinical benefits of Celacade and the
feedback the physicians received from patients."

About Celacade:

The Celacade System targets the inflammation underlying chronic
heart failure and other cardiovascular diseases. Inflammation is a
normal response of the immune system to cellular injury caused by
infection, trauma, or other stimuli. During the inflammatory
process, immune cells release a number of factors, including
cytokines - potent chemical messengers that modulate inflammation
and facilitate the healing process. While this inflammatory process
is usually self-limiting, it can persist, become chronic, and lead to
a number of serious medical conditions.

During a brief outpatient procedure, a small sample of a patient's
blood is drawn into Vasogen's Celacade single-use disposable
cartridge and exposed to controlled oxidative stress utilizing
Vasogen's proprietary Celacade medical device technology. Oxidative
stress is a factor known to initiate apoptosis, a physiologic
process that is inherently anti-inflammatory. The treated blood is
then administered to the same patient intramuscularly. An initial
course of treatment comprising three consecutive outpatient
procedures is administered over a two-week period, and treatments
are continued once per month thereafter.

About Grupo Ferrer Internacional, S.A.:

Vasogen has entered into a collaboration with Grupo Ferrer
Internacional, a privately held European research and commercial
development based pharmacochemical and medical devices company
headquartered in Barcelona, Spain. Ferrer operates today in over 60
countries with the overall aim to improve people's health and
quality of life. Based on its policy of continuous expansion
throughout the world, Ferrer has established strong industrial and
commercial operations in Europe and has extensive commercial
experience in Latin America, Africa, and in the Middle and Far East.
Ferrer has licensing, distribution, and marketing agreements with
large multinational pharmaceutical companies, as well as mid-size
firms, including AstraZeneca, Astellas, Johnson & Johnson, Merck
Sharp & Dohme, Novartis, Roche, Sanofi-Aventis, Solvay, Cephalon,
United Therapeutics, and The Medicines Co., among others. In
addition to its commercial operations, Ferrer operates
pharmaceutical research and development facilities in Barcelona,
Spain and Alsdorf, Germany. The research facilities in Barcelona
manage all aspects of drug development from concept through to
clinical development and product registration. The Alsdorf facility
is specialized in new applications of pharmaceutical technology.
Ferrer also has established research collaborations with a large
number of pharmaceutical companies and universities throughout the
world.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and
commercial development of therapies designed to target the
destructive inflammatory process associated with the development and
progression of cardiovascular and neurodegenerative disorders. The
Company's lead product, the Celacade System, is designed to activate
the immune response to apoptosis - an important physiological
process that regulates inflammation. Celacade is in late-stage
development for the treatment of chronic heart failure and has
received European regulatory approval under the CE Mark for this
indication. Vasogen is also developing a new class of drugs for the
treatment of certain neuro-inflammatory disorders. VP025 is the lead
drug candidate from this new class.

Certain statements contained in this press release or elsewhere in
our public documents constitute "forward-looking statements" within
the meaning of the United States Private Securities Litigation
Reform Act of 1995 and/or "forward-looking information" under the
Securities Act (Ontario). These statements may include, without
limitation, plans to advance the development of Celacade(TM) or
VP025, plans to fund our current activities, statements concerning
our partnering activities, health regulatory submissions, strategy,
future operations, future financial position, future revenues and
projected costs. In some cases, you can identify forward-looking
statements by terminology such as "may", "will", "should",
"expects", "plans", "anticipates", "believes", "estimated",
"predicts", "potential", "continue", "intends", "could", or the
negative of such terms or other comparable terminology. We made a
number of assumptions in the preparation of these forward-looking
statements, including assumptions about the nature, size, and
accessibility of the market for Celacade in the treatment of chronic
heart failure, particularly in Europe, the regulatory approval
process leading to commercialization and the availability of capital
on acceptable terms to pursue the development of Celacade, and the
feasibility of additional trials. You should not place undue
reliance on our forward-looking statements which are subject to a
multitude of risks and uncertainties that could cause actual
results, future circumstances or events to differ materially from
those projected. These risks include, but are not limited to, the
outcome of further ongoing analysis of the ACCLAIM trial results,
the requirement or election to conduct additional clinical trials
and the size and design of any such trials, delays or setbacks in
the regulatory approval process, difficulties in the maintenance of
existing regulatory approvals, securing and maintaining corporate
alliances, the need for additional capital and the effect of capital
market conditions and other factors on capital availability, the
potential dilutive effects of any financing, risks associated with
the outcomes of our preclinical and clinical research and
development programs, the adequacy, timing, and results of our
clinical trials, competition, market acceptance of our products, the
availability of government and insurance reimbursements for our
products, the strength of intellectual property, reliance on
partners, subcontractors, and key personnel, losses due to
fluctuations in the U.S.-Canadian exchange rate, and other risks
detailed from time to time in our public disclosure documents or
other filings with the Canadian and U.S. securities commissions or
other securities regulatory bodies. Additional risks and
uncertainties relating to our Company and our business can be found
in the "Risk Factors" section of our Annual Information Form and
Form 20-F for the year ended November 30, 2006, as well as in our
later public filings. The forward-looking statements are made as of
the date hereof, and we disclaim any intention and have no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

http://www.vasogen.com

ots Originaltext: Vasogen Inc
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada L5N 5S2; Tel:
+1-905-817-2004; Fax: +1-905-569-9231; investor@vasogen.com